Moderna, Inc. — Director's Dealing 2020

Oct 23, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-10-21

Reporting Person: HENDERSON LORI M. (General Counsel and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-21	Common Stock	M	32000	$14.85	Acquired	32681	Direct
2020-10-21	Common Stock	S	1697	$68.70	Disposed	30984	Direct
2020-10-21	Common Stock	S	14148	$69.84	Disposed	16836	Direct
2020-10-21	Common Stock	S	15455	$70.56	Disposed	1381	Direct
2020-10-21	Common Stock	S	700	$71.39	Disposed	681	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-21	Stock Option (Right to Buy)	$14.85	M	32000	Disposed	2028-06-26	Common Stock (32000)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2020.

F2: Includes 681 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 29, 2020.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.20 to $69.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.25 to $70.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.27 to $71.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.34 to $71.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.